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Abstract 
Background: In India, the recommended first-line treatment for malaria in the second and third trimester of preg-
nancy is artesunate + sulfadoxine-pyrimethamine (AS+SP). However, data on safety and efficacy of artemisinin-based 
combination therapy (ACT) in pregnancy is limited. This study assessed the safety and efficacy of AS+SP and artesu-
nate + mefloquine (AS+MQ) for treatment of Plasmodium falciparum in pregnancy in India.
Methods: This open-label, randomized clinical trial was conducted from October 2010 to December 2013 at three 
sites in India (Ranchi and Jamshedpur in Jharkhand state, and Rourkela in Odisha state). Pregnant women in the 
second or third trimester who had P. falciparum mono-infection of any parasite density with or without fever were 
randomized to receive AS+SP or AS+MQ. Blood slides and filter paper samples for Polymerase Chain Reaction (PCR) 
were collected on days 0, 1, 2, 3, 14, 21, 28, 42 and 63 post treatment. Women were followed up at delivery and at day 
42 postpartum.
Findings: Two hundred and forty-eight women of 7064 pregnant women (3.5%) who were screened at monthly 
antenatal clinics had a P. falciparum mono-infection and were randomized to receive AS+SP (125) or AS+MQ (123) 
and all of these women were included in the intention to treat (ITT) analysis. The primary endpoint of an adequate 
clinical and parasite response (ACPR) on day 63 was not available for 9 women who were counted as treatment failure 
in the ITT analysis. In the ITT population, the ACPR was 121/125 (96.8%; 95% Confidence interval (CI) 92.0–99.1%) in 
the AS+SP group and 117/123 (95.1%; 95% CI 89.7–98.2) in the AS+MQ group. Among the 239 women (121 from the 
AS+SP arm and 118 from the AS+MQ arm) who completed the day 63 follow up (per protocol analysis) the ACPR was 
100% in the AS+SP group and 99.2% (117/118) in the AS+MQ group. There were five serious adverse events (SAE) 
among pregnant women (4 in the AS+SP group and 1 in the AS+MQ group) and 13 fetal/neonatal SAEs (7 in the 
AS+SP group and 6 in the AS+MQ) but none of them were related to the study drugs. A higher proportion of women 
in the AS+MQ arm reported vomiting within 7 days post-treatment than did women in the AS+SP arm (6.9 vs. 1.6%; 
p = 0.001).
Conclusion: Both AS+SP and AS+MQ are safe and effective for treatment of uncomplicated falciparum malaria in 
pregnancy in India.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Malaria continues to be a major public health challenge in 
India with about one million cases reported annually [1]. 
The burden of malaria in India varies markedly between 
different ecological zones, but it is estimated that about 
two percent of pregnant women suffer from malaria in 
endemic areas [2, 3]. Malaria is known to cause fetal as 
well as maternal complications during pregnancy [4]. 
Timely diagnosis and treatment of malaria in pregnancy 
is of utmost importance to prevent complications in this 
vulnerable group [5]. Until 2010, the Indian national 
policy for treatment of malaria in pregnancy (MiP) was 
chloroquine for Plasmodium vivax and quinine for Plas-
modium falciparum infections in all trimesters. Since 
2011, artesunate + sulfadoxine-pyrimethamine (AS+SP) 
has become the recommended treatment for falcipa-
rum malaria in the second and third trimesters of preg-
nancy [6]. Although there are reports of the emergence 
of resistance to SP in some parts of India [7], AS+SP was 
found effective for treatment of uncomplicated malaria 
in non-pregnant adults in India [8]. Artemisinin + meflo-
quine (AS+MQ) was also found to be safe and effective 
in non pregnant adults in India [9]. Evidence from other 
countries suggest that artemisinin-based combination 
therapy is superior to quinine-based therapy [10]. AS+SP 
and AS+MQ were found safe and effective in pregnant 
women in Malawi and Zambia, respectively [11, 12]. 
However, there is no data on the safety or efficacy of any 
form of artemisinin-based combination therapy (ACT) in 
malaria in pregnancy from India. The safety and efficacy 
of AS+SP and AS+MQ was assessed for treatment of P. 
falciparum malaria in pregnancy in two eastern states in 
India.
Methods
This individually randomized, open label trial was con-
ducted among pregnant women at three sites in India. 
Two sites (Ranchi and Jamshedpur) are in Jharkhand 
state and the third site (Rourkela) is in Odisha state. In 
all three sites, malaria transmission is perennial and the 
majority of the malaria cases are due to P. falciparum 
[13].
Enrolment into cohort of pregnant women
After obtaining written informed consent, preg-
nant women were screened for malaria at monthly, 
public antenatal clinics (ANC) in the catchment area of 
the three study hospitals. At enrolment into the cohort 
and at each subsequent, monthly ANC visit, blood slides 
were collected from all women irrespective of whether 
they had a history of fever or not. In addition, women 
who had fever or a history of fever were tested with a 
malaria rapid diagnostic test (RDT) malaria Pf dipstick 
RDT (Guangzhou Wondfo Biotech Co. Ltd. China). If 
tested positive, they were referred to the study hospital 
for further assessment. All blood slides collected were 
examined on the same day. Women with a positive blood 
slide were invited to the study hospital the same day to 
assess eligibility. Women who fulfilled the inclusion crite-
ria were enrolled into the trial and admitted to the study 
hospital for treatment.
Pregnant women of the study cohort of any parity in 
the 2nd or 3rd trimester who had a P. falciparum mono-
infection were eligible for enrolment. The gestational 
age was determined by ultrasound. Women having any 
of the following conditions were excluded: (i) Hb < 7  g/
dL; (ii) gestation of < 12 or > 36 weeks; (iii) age < 18 years 
(iv) abnormal liver or renal function tests; (v) a history 
of taking an anti-malarial within the past 7  days; (vi) a 
history of allergy to any of the study drugs; (vii) taking 
part in any other clinical trial of drugs or vaccines; (viii) 
severe malaria (based either on clinical presentation or 
hyperparasitaemia); (ix) evidence of severe concomitant 
infection; (x) known chronic disease (cardiac, haemoglo-
binopathy); (xi) a history of convulsions during the pre-
sent illness or a history of psychiatric disorder or seizures 
(xii) vivax malaria or a mixed infection.
Sample size
Initially, it was estimated that 500 pregnant women with 
P. falciparum malaria would be needed for inclusion in 
the trial based on the following assumptions: (1) day 
63 adequate clinical and parasite response (ACPR) for 
AS+SP would be 85%, and that for AS+MQ it would be 
95%; (2) loss to follow up would be < 20%; (3) the power 
of the study would be 90% to detect a 10% difference in 
ACPR between the treatment groups at a 95% signifi-
cance level. Because of very low treatment failures in 
both arms and a lower than expected enrolment rate the 
sample size was subsequently revised to 300. Study enrol-
ment was stopped at the end of the malaria transmission 
season in December 2013 when a total of 248 pregnant 
women were enrolled.
Trial registration CTRI This study is registered with Clinical Trial Registry India (CTRI), number CTRI/2009/091/001055. 
Date of Registration 11 January 2010, http://ctri.nic.in/Clini caltr ials/pmain det2.php?trial id=1185&EncHi d=&userN 
ame=anvik ar
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Randomization
Treatment allocation envelopes were prepared by an 
independent statistician in permuted blocks of 12 for 
each site. Eligible participants were randomly assigned 
to either AS+SP or AS+MQ arm by selecting a sealed 
envelope that contained the treatment code; envelopes 
were labeled with unique identifier numbers and kept 
sequentially.
Treatment
Enrolled women were admitted to the study hospi-
tals for 3  days for administration of the study drugs. 
They received either AS+SP (artesunate 200  mg 
daily for 3  days and sulfadoxine 1500  mg + pyrimeth-
amine 75  mg on day one) or AS+MQ (artesunate 
200 mg + mefloquine 440 mg daily for 3 days).
Definitions of birth outcomes
Miscarriage was defined as loss of the fetus before 
28 weeks of gestation. Abortion was defined as prema-
ture expulsion of the products of conception from the 
uterus. Intrauterine death defined as fetal death prior 
to complete expulsion or extraction from the mother. 
Stillbirth: baby born with no signs of life at or after 
28 weeks’ gestation.
Assessments
During the first 3  days of treatment, women were 
assessed in hospital. Study participants were then 
requested to come for follow up visits on days 7, 14, 
21, 28, 42 and 63 post-treatment. Women who missed 
follow-up visits were visited at home by the study team. 
A blood slide and filter paper sample were collected 
on day 0, 1, 2, 3, 7, 14, 21, 28, 42 and 63. Venous blood 
samples for haemoglobin (Hb) measurement, renal and 
liver function tests were collected at enrolment and on 
days 14 and 63. Adverse events were assessed at each 
scheduled and unscheduled visit and treated in a study 
hospital when appropriate.
After the initial 63-day follow-up period, women 
were seen at monthly ANC clinics and were encouraged 
to deliver at one of the study hospitals. They were given 
free transport to reach the study hospital for delivery 
and postnatal care.
At delivery, peripheral blood samples and placental 
biopsy samples were collected for all institutional deliv-
eries. When deliveries occurred outside the facility, 
home visits were conducted as soon as possible after 
birth by a study midwife. Birth-weight, gestational age 
(Ballard score), and the presence of congenital abnor-
malities were assessed at delivery or within 7  days 
of birth. All participants were followed up on day 42 
post-partum to assess the health status of the mother 
and her baby.
Rules for administration of rescue therapy with quinine 
were: (1) early or late treatment failure; (2) > 3 g/dL drop 
in haemoglobin or a haemoglobin level < 7  g/dL during 
treatment. The rule for stopping the trial was an unac-
ceptable frequency of adverse events. The Data Safety 
and Monitoring Board (DSMB) reviewed data regularly 
and had the authority to recommend to the sponsor stop-
ping the trial if they had major concerns.
Laboratory methods
Thick and thin blood films were Giemsa-stained and 
examined by two microscopists for species identification. 
Parasite density was ascertained by counting asexual par-
asites against 200 white blood cells in the thick film. Par-
asites were counted against 500 WBCs if the count was 
less than 99 parasites per 200 WBCs. For determining the 
parasite density, a white blood cell count of 8000/μL was 
assumed. For discordant readings on parasite density the 
mean was taken if the difference was < 25%. For any other 
discordant results, the slides were read by a third micros-
copist whose findings were considered as the final result.
In cases of treatment failures, PCR genotyping was car-
ried out to differentiate between recrudescent and new 
P. falciparum infections following WHO PCR genotyp-
ing guidelines [14]. Genotyping was done sequentially 
using the molecular markers msp2, msp1 and glurp. PCR 
analysis was done at the National Institute for Malaria 
Research (NIMR) in Delhi on paired blood samples col-
lected on day zero and on the day of failure.
Data management
Case Report Forms (CRFs) were filled manually. GCP-
monitoring, including source data verification, was done 
for all CRFs before data was double entered and verified 
in OpenClinica. Data processing and analysis was done 
using the statistical software package STATA Version 
IC12.0 (STATA TM, Stata Corp, USA).
Statistical analyses
Baseline characteristics at enrolment, parasite clearance 
rates and birth outcomes were summarized and com-
pared across treatment groups. Binominal exact method 
was used to calculate confidence intervals. Chi square 
test and t test were used to test the level of significance 
for categorical and continuous variables, respectively. 
The primary trial endpoint, adequate clinical and para-
site response (ACPR), was defined as absence of parasite 
from day 3 until day 63 post-treatment. Treatment effi-
cacy was assessed in the intention to treat (ITT) popu-
lation, which included all women enrolled in the study, 
and in the per protocol (PP) population, which included 
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all women who had completed treatment and the follow 
up on day 63. In addition, a Kaplan–Meier (KM) sur-
vival analsysis was performed to compare the probabil-
ity of treatment failure in both study arms, censoring the 
women when they were lost to follow up. Safety analysis 
was performed in the ITT population.
Ethics
The protocol was approved by Ethics Committees of 
NIMR, Ispat General Hospital Rourkela and the London 
School of Hygiene and Tropical Medicine, London, UK 
(LSHTM). Written informed consent was obtained from 
all participants. An independent Data Safety Monitoring 
Board consisting of an obstetrician, statistician, pharma-
cologist and clinician monitored the safety and progress 
of the study.
The study is registered with Clinical Trial Registry 
India (CTRI), number CTRI/2009/091/001055.
Results
Between October 2010 and December 2013, a total of 
7064 pregnant women were screened at public ANC 
facilities. A total of 248 women (3.5%) were enrolled into 
the trial (Fig. 1). Forty women were excluded due to the 
presence of a mixed infection (4), a P. vivax infection (11), 
severe malaria (9), RDT positive but blood slide negative 
(4), intrauterine death (3), jaundice (2), renal disease (1), 
gestation > 36 weeks (4) and gestation < 12 weeks (2).
Mean age, gestational age, Hb concentration and par-
asite density at enrolment were comparable between 
the two study arms (Table  1). On the day of enrol-
ment, 64.5% (160/248) of women reported a history of 
fever but only 24.6% (61/248) had an axillary tempera-
ture > 37.5  °C. The parasite clearance rate was similar 
among women in the two study arms. At enrolment, 
ten women had gametocytes. By day 7 all cleared game-
tocytes, except one subject which only cleared them 
by day 21. On day 3 all analysable women (246; 123 
in AS+SP and 123 in AS+MQ) were free of parasites. 
All women enrolled in the trial were included in ITT 
analysis. The number of women deemed to be treat-
ment failure due to loss to follow up were 4 in AS+SP 
group and 5 in the AS+MQ group. In the ITT popu-
lation, the day 63 ACPR was 96.8% (121/125; (95% CI 
92.0–99.1%) in the AS+SP group and 95.1% (117/123; 
95% CI 89.7–98.2) in the AS+MQ group (Table  2). In 
the PP population (121 from the AS+SP group and 118 
from the AS+MQ group) no women had a treatment 
failure in the AS+SP group and in this group the ACPR 
on day 63 was 100% (95% CI 97–100%). In the AS+MQ 
group, one woman had parasitaemia on day 63 (3200 
parasites/µL). By PCR genotyping it was shown to be a 
re-infection with P. falciparum.. The PCR-uncorrected 
ACPR on day 63 in the AS + MQ group was 99.2% 
(117/118; 95% CI 95.4–100). Following PCR correction, 
it was 100% (118/118; 95% CI 96.9–100). The results 
of the Kaplan–Meier survival analysis showed no dif-
ference in the probability of treatment failure in both 
arms. The KM graph is available as Additional file 1.
There were five maternal SAEs, four in the AS+SP 
group and one in the AS+MQ group. In the AS+SP 
group, the SAEs were one maternal death, hospitaliza-
tion due to oligohydramnios (2) and antepartum haem-
orrhage (1). The maternal death occurred on day Five 
due to complications of severe malaria. This woman had 
high parasitaemia on day 0 (205,440 parasites/µL) and, 
therefore, should have not been enrolled. In the AS+MQ 
arm there was one hospitalization due to a urinary tract 
infection. None of the serious adverse events were con-
sidered related to the study drugs. There were 13 fetal or 
neonatal SAEs, 7 in AS+SP and 6 in AS+MQ arm. The 
causes of fetal/neonatal SAEs in the AS+SP group were 
intrauterine death (4), neonatal jaundice (2), still birth 
(1). In the AS+MQ group they were intrauterine death 
(2), asphyxia (1), aspiration pneumonia (1) and still birth 
(2). None of these events were considered related to the 
study drugs.
The observed and reported adverse events during the 
first week following treatment are shown in Table 3. The 
proportion of women who reported vomiting was signifi-
cantly higher in the AS+MQ group than in the AS+SP 
group (6.9 vs. 1.6%; p = 0.001). A substantial proportion 
of women reported dizziness and weakness in both arms. 
The mean values of haematological and biochemical 
parameters did not show any significant change from day 
0 to day 14 in either arm (Table 4).
Birth outcomes were available for 97.2% (241/248) 
women (121 in the AS+SP group and 120 in the AS+MQ 
group). The sex ratio was 843 females per 1000 males. 
The occurrence of low birth weight (< 2.5 kg) was higher 
in the AS+SP arm than in the AS+MQ arm (28.1 vs. 
16.7%; p < 0.01) (Table 5). There was no statistically signif-
icant difference in miscarriages, preterm delivery or still-
births between the two groups. Although Ballard score 
was used to assess gestational age, it is not presented in 
the manuscript as the authors were not sufficiently con-
fident about the accuracy of the SGA diagnosis. No con-
genital malformations were observed. A placental biopsy 
sample was available for 75% (181/241) women; none 
showed active placental malaria defined by the presence 
of parasites. At delivery, one woman of each treatment 
group was found blood slide positive. Both deliveries 
took place 1, and 2 months, respectively after the day 63 
follow up in AS+SP and AS+MQ arms. The two women 
were treated according to national policy (AS+SP). No 
evidence of congenital malaria was found.
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Discussion
This is the first trial of ACT in pregnant women in 
India to evaluate the efficacy and safety of AS+SP and 
AS+MQ. The incidence of malaria in the cohort of 
pregnant women screened at monthly intervals was 4.1% 
(288/7064). Due to these low patient numbers it was not 
possible to reach the original targeted sample size of 500 
Fig. 1 Trial consort diagram
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women. However, a clear result was obtained despite the 
reduced sample size.
Results from this study suggests that AS+SP and 
AS+MQ are both efficacious for the treatment of MiP 
in India. The day 63 ACPR and PCR-corrected ACPR 
were 100% in both groups in the PP population and > 95% 
in the ITT population. Reasons for the high efficacy 
observed could be that very few people in the study area 
had been exposed to any ACT at the time the trial was 
conducted, and that the parasite density was relatively 
low (mean parasitaemia 16,695/µL) at recruitment. The 
low parasite density is partly due to the fact that the 
majority of the trial participants was detected by active 
screening and did not have clinical symptoms at enroll-
ment; on the day of enrollment only 24.6% of women had 
fever or a history of clinical symptoms.
The efficacy of AS+MQ and AS+SP observed in this 
study is consistent with that reported from India in 
non-pregnant adult populations. The day 63 ACPR of 
AS+MQ was 100% in 2005–2007 [15] and 98.3% (95% 
CI 90.9–99.9) in 2008 [9]. In another study carried out in 
2009–2010, the day 42 PCR corrected ACPR of AS+MQ 
was 100% (95% CI 92.7–100) and that of AS+SP was 
90.6% (95% CI 89.2–90.9) [16]. However, a high preva-
lence of triple (55.5%) and quadruple (23.2%) mutation in 
dhps gene was observed [7] in the north eastern states, 
and recent in  vivo studies have shown that the efficacy 
of AS + SP is declining in these states [7, 17]. The day 
42 PCR corrected ACPR of AS+SP ranged from 76.6 to 
82.3% across sites in the north-eastern region [7]. Thus, 
AS+SP needs to be replaced with other artemisinin-
based combinations in this region. In a multi-country 
trial in pregnant women, the day 63 PCR corrected ACPR 
was 94.8% (95% CI 93–96.1) for artemether-lumefantrine 
(AL), 99.2% (95% CI 98.2–99.6) for dihydroartemisinin-
piperaquine (DHAPQ), 98.5% (95% CI 97.3–99.2) for 
artesunate-amodiaquine (AS+AQ) and 96.8% (95% 
CI 95.2–97.9) for AS+MQ [18]. A review article ana-
lysed the results from 48 efficacy studies. They suggest 
that artemisinin-based combinations are superior to 
Table 1 Baseline characteristics at enrolment, by treatment group
a Mean ± SD; percentages in brackets
AS+SP (N = 125) AS+MQ (N = 123) Total (N = 248) P-value
Age (years)a 23.1 ± 3.9 23.6 ± 3.7 23.4 ± 3.8 0.2758
Gestation (weeks)a 25.5 ± 6.2 24.8 ± 5.7 25.14 ± 5.95 0.3660
Hb (g/dL)a 8.8 ± 1.1 9.1 ± 1.3 8.96 ± 1.2 0.1126
Asexual parasitaemia/µLa [median 
(range)]
16,261 ± 30,494 [2800 
(32–165,520)]
17,126 ± 30,705 [2220 (32–
153,000)]
16,695 ± 30,540 [2400 
(32–165,520)]
0.8257
Gametocyte carriage 5 (4.0) 5 (4.1) 10 (4.0)
Gravidity
 1 57 (45.6) 52 (42.3) 109 (44.0) 0.5998
 2 37 (29.6) 38 (30.9) 75 (30.2) 0.8253
 3+ 31 (24.8) 33 (26.8) 64 (25.8) 0.7163
Parity
 0 64 (51.2) 61 (49.6) 125 (50.4) 0.8012
 1 36 (28.8) 40 (32.5) 76 (30.6) 0.5271
 2+ 25 (20.0) 22 (17.9) 47 (19.0) 0.6726
Table 2 Parasitaemia from day 0 until day 63
Treatment day 0 ASSP N (%) ASMQ N (%)
Positive blood slide 125 123
Mean parasite density/μL 16,261 ± 30,494 17,126 ± 30,705
Post treatment day
 Day 1
  Positive blood slide 24/124 (19.4) 28/123 (22.8)
  Mean parasitaemia/μL 173 ± 777 1568 ± 8958
 Day 2
  Positive blood slide 3/123 (2.4) 2/123 (1.6)
  Mean parasitaemia/μL 0.72 ± 4.8 2.1 ± 14.8
 Day 3
  Positive blood slide 0/123 0/123
 Day 7
  Positive blood slide 0/123 0/122
 Day 28
  Positive blood slide 0/122 0/121
 Day 42
  Positive blood slide 0/122 0/121
 Day 63
  Positive blood slide 0/121 1/118
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quinine-based therapy [10]. Studies carried out in India 
in non-pregnant adults and children have shown a high 
efficacy of AL [19], AS+AQ [20], AS+MQ and DHAPQ 
[15]. These artemisinin-based combinations are potential 
options to replace AS+SP in India, but there is a need to 
evaluate them in pregnant women in India.
In this study, no serious adverse events related to 
AS+SP or AS+MQ were reported. However, as the sam-
ple size was just 248 subjects, the safety findings from 
this study need to be interpreted with caution. The inci-
dence of vomiting was significantly higher in women who 
received AS+MQ than in those who received AS+SP 
which confirms the finding of a high incidence of vomit-
ing when MQ was used for intermittent preventive treat-
ment in pregnant women [21]. The PREGACT study also 
reported a high frequency of vomiting in AS+MQ group 
[18].
The observed prevalence of low birth weight (22.4%), 
pre-term delivery (16.6%) and stillbirth (1.7%) was com-
parable to the results of a study carried out in Jharkhand 
state in 2009 [2], where the prevalence of low birth 
weight, pre-term delivery and stillbirth was reported 
in women with/without placental parasitaemia at 
26.7%/20.9%, 13.3%/5.6% and 11.8%/4.1%, respectively. 
There was a higher proportion of low birth weight, pre-
term delivery and miscarriage in AS+SP arm compared 
to AS+MQ arm. Although the risk of low birth weight 
was significantly higher in the AS+SP arm, this finding 
needs to be interpreted with caution because of the small 
sample size and of the multiple comparisons that were 
done.
Conclusion
Both AS+SP and AS+MQ are equally effective for the 
treatment of falciparum malaria in second and third tri-
mester pregnancies in the central region of India. AS+SP 
was tolerated better than AS+MQ but it appears that 
AS+MQ may be slightly more effective than AS+SP at 
reducing adverse birth outcomes. Given that resistance 
to SP has emerged and is spreading in India, the risk ben-
efit ratio of other artemisinin-based combinations (such 
as DHAPQ and AL) needs to be evaluated in pregnant 
women in India.
Table 3 Observed and/or  reported adverse events 
during the first 7 days after the start of treatment
Event ASSP 
(n = 125) 
N (%)
ASMQ 
(n = 123) 
N (%)
Total 
(n = 248) 
N (%)
p-value
Anaemia (< 11 g/dL) 18 (14.4) 17 (13.8) 35 (14.1) 0.896
Weakness 22 (17.6) 19 (15.4) 41 (16.5) 0.648
Nausea 4 (3.2) 9 (7.3) 13 (5.2) 0.146
Vomiting 2 (1.6) 15 (12.2) 17 (6.9) 0.001
Headache 7 (5.6) 3 (2.4) 10 (4.0) 0.206
Diarrhoea 2 (1.6) 6 (4.9) 8 (3.2) 0.144
Dizziness 11 (8.8) 12 (9.8) 23 (9.3) 0.795
Lower abdominal pain 8 (6.4) 4 (3.3) 12 (4.8) 0.248
Pruritus 2 (1.6) 1 (0.8) 3 (1.2) 0.571
Tinnitus 5 (4.0) 5 (4.1) 10 (4.0) 0.979
Table 4 Haematological and biochemical findings 
in women in each treatment group on day 0 and 14
Biochemical parameter ASSP ASMQ
Day 0 Day 14 Day 0 Day 14
Haemoglobin (g/dL) 8.5 8.6 8.6 8.7
RBC (million/mm3) 3.9 3.9 3.9 3.9
WBC (/mm3) 8332 8096 7712 7872
Total bilirubin (iu/L) 0.6 0.5 0.8 0.5
SGOT (iu/L) 35.84 28.12 29.2 26
SGPT (iu/L) 30.92 21.2 17.96 16.84
Blood urea (mg/dL) 23.72 20.52 24.88 20.8
Creatinine (mg/dL) 0.80 0.80 0.79 0.76
Alkaline phosphatase (iu/L) 284.64 246.6 258.96 224.8
Table 5 Birth outcome in the AS+SP and AS+MQ groups
Birth outcomes available ASSP n (%) 121 ASMQ n (%) 120 Total n (%) 241 p-value
Mean birth weight ± SD 2569.7 ± 471.5 2684.5 ± 407.9 2627.8 ± 443.2 0.048
Low birth weight (< 2.5 kg) including 
pre-term deliveries
34 (28.1) 20 (16.7) 54 (22.4) 0.027
Low birth weight (< 2.5 kg) excluding 
pre-term deliveries
19 (15.7) 18 (15.0) 37 (15.4) 0.081
Term delivery 97 (80.2) 99 (82.5) 196 (81.3) 0.312
Pre-term delivery 22 (18.2) 18 (15) 40 (16.6) 0.403
Miscarriage 1 (0.8) 1 (0.8) 2 (0.8) 0.991
Stillbirth 1 (0.8) 3 (2.5) 4 (1.7) 0.317
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